Form 4: BridgeBio Pharma Director Acquires Stock Units

BridgeBio Pharma, Inc. reports a Form 4 filing detailing the acquisition of restricted stock units and stock options by Director Andrew Lo.

Summary

• Andrew Lo, a Director at BridgeBio Pharma, Inc., acquired 3,990 restricted stock units (RSUs) on June 22, 2026, with a reported acquisition price of $0.
• These RSUs are part of the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan and are set to vest in full on June 22, 2027, contingent upon continued service.
• Additionally, Lo acquired a stock option to buy 5,277 shares of common stock at an exercise price of $68.92, with an expiration date of June 21, 2036.
• The shares underlying this stock option also vest in full on June 22, 2027, subject to continued service.
• Following these transactions, Lo beneficially owns 18,079 shares of common stock, held indirectly through a joint tenancy with right of survivorship with Nancy N. Lo.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents standard equity awards to a director rather than significant financial performance or strategic shifts.

Positives

• Director Andrew Lo's acquisition of RSUs and stock options indicates continued commitment and alignment with the company's long-term performance.
• The grant of equity awards suggests a strategy to incentivize and retain key leadership personnel.

Negatives

• The acquisition of stock options at an exercise price of $68.92 may indicate that the current market price is below this level, or that the option is intended for future appreciation.
• The vesting schedule tied to continued service means the full benefit of these awards is contingent on Lo remaining with the company.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning any departure before June 22, 2027, would result in forfeiture of these awards.
• The stock option exercise price of $68.92 implies a significant increase in share price is needed for the option to be profitable.

Future Outlook

The future outlook for these specific equity awards is tied to the continued service of Director Andrew Lo and the future performance of BridgeBio Pharma's stock, which would need to exceed the $68.92 exercise price for the stock options to be in-the-money.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the biopharmaceutical industry to align executive interests with shareholder value and to attract and retain talent in a competitive landscape.

Stakeholder Impact

• Shareholders: The issuance of equity awards to directors is a standard compensation practice that can align management and shareholder interests, potentially leading to long-term value creation.
• Employees: The incentive plan under which these awards were granted may also be available to other employees, fostering a culture of ownership and performance.
• Management: Director Andrew Lo's compensation is directly linked to his continued service and the company's stock performance.

Next Steps

• Continued service by Andrew Lo through June 22, 2027, to ensure vesting of RSUs and stock options.
• Monitoring of BridgeBio Pharma's stock performance relative to the $68.92 stock option exercise price.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Andrew Lo, Director, SEC Filing, Equity Awards